Royalty Pharma 

Royalty Pharma 

Yahoo Finance • yesterday

Royalty Pharma Q3 2026 Earnings Preview

* Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) is scheduled to announce Q3 earnings results on Wednesday, November 4th, before market open. * The consensus EPS Estimate is $1.18 [https://seekingalpha.com/symbol/RPRX/ear... Full story

Yahoo Finance • 7 days ago

Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings Loom

Funds played defense as they load up on Marriott, Estee Lauder and biotech and energy names in Tuesday's stock market. Continue Reading... Full story

Yahoo Finance • 23 days ago

United Healthcare (UNH): Early-Stage Earnings Recovery Sets the Stage for Mid-Teens Compound Growth

Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the "Patient Opportunity Equity Strategy". The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in t... Full story

Yahoo Finance • 23 days ago

Royalty Pharma (RPRX) Offers Attractive Risk-Reward Profiles at Reasonable Multiples

Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the "Patient Opportunity Equity Strategy". The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in t... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • 2 months ago

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprot... Full story

Yahoo Finance • 2 months ago

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

Royalty Pharma plc NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied... Full story

Yahoo Finance • 3 months ago

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy target... Full story

Yahoo Finance • 3 months ago

Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance

This article first appeared on GuruFocus. Portfolio Receipts: Grew 6% in Q2 2026 to $773 million, ahead of expectations. Royalty Receipts: Grew 14% in Q2 2026, driven by strong performances from Tremfya, Voranigo, Emdeltra, and Evrysdi. T... Full story

Yahoo Finance • 3 months ago

Royalty Pharma Q2 26 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Royalty Pharma plc (RPRX) will host a conference call at 8:00 AM ET on August 5, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to https://www.royaltypharma.com/investors/events/ The views and opi... Full story

Yahoo Finance • 3 months ago

Royalty Pharma reports second quarter 2026 results

Royalty Pharma plc Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million... Full story

Yahoo Finance • 3 months ago

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including... Full story

Yahoo Finance • 4 months ago

Royalty Pharma declares third quarter 2026 dividend

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid... Full story

Yahoo Finance • 4 months ago

Royalty Pharma, plc (RPRX) Rallied on Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for "Meridian Hedged Equity Fund". A copy of the letter can be downloaded here. The Fund invests in high-quality growth companies and mitigates... Full story

Yahoo Finance • 5 months ago

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m.... Full story

Yahoo Finance • 6 months ago

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally

On May 8, 2026, CM Management reported selling its entire 200,000-share stake in Centerra Gold(NYSE:CGAU), an estimated $3.56 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commissi... Full story

Yahoo Finance • 6 months ago

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge

On May 8, 2026, CM Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold its entire stake in Preformed Line Products(NASDAQ:PLPC), an estimated $6.39 million trade based on quarterly average pricing.... Full story

Yahoo Finance • 6 months ago

Royalty Pharma plc Q1 2026 Earnings Call Summary

Royalty Pharma plc Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Delivered 13% growth in recurring royalty receipts, driven by a diversified portfolio and the absorption of the Promacta loss of exclusi... Full story

Yahoo Finance • 6 months ago

Royalty Pharma reports Q1 results; raises FY26 outlook

* Royalty Pharma press release [https://seekingalpha.com/pr/20502630-royalty-pharma-reports-first-quarter-2026-results] (RPRX [https://seekingalpha.com/symbol/RPRX]): Q1 Revenue of $631M (+11.1% Y/Y) misses by $243.12M. * Portfolio Rec... Full story

Yahoo Finance • 6 months ago

Royalty Pharma reports first quarter 2026 results

Royalty Pharma plc Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million... Full story